
The systematic review explores the impact of C-reactive protein (CRP) levels on the effectiveness of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in treating renal anemia in chronic kidney disease (CKD) patients. Analyzing data from 7 studies, the study compares patients with CRP levels above and below the upper limit of normal (ULN). Results show no significant difference in hemoglobin concentration changes between the two groups. Within the high CRP group, roxadustat maintains efficacy comparable to erythropoiesis-stimulating agents (ESAs) without requiring dose escalation. This suggests roxadustat's consistent efficacy across CRP levels and its potential advantage over ESAs in managing renal anemia.
Like
Save
Share